carvedilol has been researched along with ST Elevated Myocardial Infarction in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-Scale Randomized Controlled Trial), patients with STEMI with successful percutaneous coronary intervention with an LVEF of ≥40% were randomly assigned to carvedilol or no β-blocker therapy." | 7.30 | Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction. ( Akao, M; Amano, M; Bingyuan, B; Furukawa, Y; Inada, T; Inuzuka, Y; Izumi, C; Kadota, K; Kaji, S; Kimura, T; Minamimoto, Y; Miyake, M; Morimoto, T; Nakagawa, Y; Ozasa, N; Suwa, S; Suzuki, T; Tamura, T; Watanabe, H, 2023) |
| " In the CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-Scale Randomized Controlled Trial), patients with STEMI with successful percutaneous coronary intervention with an LVEF of ≥40% were randomly assigned to carvedilol or no β-blocker therapy." | 3.30 | Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction. ( Akao, M; Amano, M; Bingyuan, B; Furukawa, Y; Inada, T; Inuzuka, Y; Izumi, C; Kadota, K; Kaji, S; Kimura, T; Minamimoto, Y; Miyake, M; Morimoto, T; Nakagawa, Y; Ozasa, N; Suwa, S; Suzuki, T; Tamura, T; Watanabe, H, 2023) |
| "The carvedilol dose was up-titrated from 3." | 2.87 | Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. ( Abe, M; Akao, M; Bingyuan, B; Furukawa, Y; Hayashi, Y; Hibi, K; Ikeguchi, S; Inada, T; Izumi, C; Kadota, K; Kaji, S; Kametani, R; Kaneko, H; Kawai, K; Kimura, T; Morimoto, T; Nakagawa, Y; Nakamura, S; Nanasato, M; Okutsu, M; Ozasa, N; Shiomi, H; Sone, T; Sugimura, Y; Suwa, S; Suzuki, T; Watanabe, H, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, M | 1 |
| Izumi, C | 2 |
| Watanabe, H | 2 |
| Ozasa, N | 2 |
| Morimoto, T | 2 |
| Bingyuan, B | 2 |
| Suwa, S | 2 |
| Miyake, M | 1 |
| Tamura, T | 1 |
| Nakagawa, Y | 2 |
| Kadota, K | 2 |
| Inuzuka, Y | 1 |
| Minamimoto, Y | 1 |
| Furukawa, Y | 2 |
| Kaji, S | 2 |
| Suzuki, T | 2 |
| Akao, M | 2 |
| Inada, T | 2 |
| Kimura, T | 2 |
| Zafeiropoulos, S | 1 |
| Stavrakis, S | 1 |
| Gupta, A | 1 |
| Das, SR | 1 |
| Pandey, A | 1 |
| Shiomi, H | 1 |
| Ikeguchi, S | 1 |
| Hibi, K | 1 |
| Hayashi, Y | 1 |
| Nanasato, M | 1 |
| Okutsu, M | 1 |
| Kametani, R | 1 |
| Sone, T | 1 |
| Sugimura, Y | 1 |
| Kawai, K | 1 |
| Abe, M | 1 |
| Kaneko, H | 1 |
| Nakamura, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial[NCT01155635] | Phase 4 | 801 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for carvedilol and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction.
Topics: Carvedilol; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; ST Ele | 2023 |
Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Carvedilol; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Percutaneous Coronar | 2018 |
2 other studies available for carvedilol and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Preserved Systolic Function: A Long-Standing Conundrum.
Topics: Carvedilol; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
β-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contraindications, Drug; Electrocardiography; H | 2018 |